RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

BACKGROUND: BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz, C, Castroviejo-Bermejo, M, Gutiérrez-Enríquez, S, Llop-Guevara, A, Ibrahim, Y H, Gris-Oliver, A, Bonache, S, Morancho, B, Bruna, A, Rueda, O M, Lai, Z, Polanska, U M, Jones, G N, Kristel, P, de Bustos, L, Guzman, M, Rodríguez, O, Grueso, J, Montalban, G, Caratú, G, Mancuso, F, Fasani, R, Jiménez, J, Howat, W J, Dougherty, B, Vivancos, A, Nuciforo, P, Serres-Créixams, X, Rubio, I T, Oaknin, A, Cadogan, E, Barrett, J C, Caldas, C, Baselga, J, Saura, C, Cortés, J, Arribas, J, Jonkers, J, Díez, O, O’Connor, M J, Balmaña, J, Serra, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961353/
https://www.ncbi.nlm.nih.gov/pubmed/29635390
http://dx.doi.org/10.1093/annonc/mdy099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961353/
https://www.ncbi.nlm.nih.gov/pubmed/29635390
http://dx.doi.org/10.1093/annonc/mdy099

Ejemplares similares